Category: Health Services, Technology

Global Progressive Supranuclear Palsy Treatment Markett is estimated to be 24.0 Million by 2029 with a CAGR of 5.3% during the forecasted period. Key Highlights: In September 2019, UCB S.A., a global biopharmaceutical company based in Belgium focusing on the discovery and development of innovative medicines and solutions, released a new data for UCB0107, an anti-Tau immunotherapy Phase I study results at World Movement Disorders Conference, France. UCB0107 is a recombinant, humanized, full-length IgG4 monoclonal antibody, a potential treatment for patients with progressive supranuclear palsy (PSP). In February 2019, AlzProtect, a biopharmaceutical company engaged in the development of medicine announced about its successful completion of the latest phase 1 study about the effect of food intake for its medicine candidate AZP2006. AZP2006 (EZEPROGIND), is a bioavailable neurotrophic inducer, targeting causes of neurodegeneration diseases.